CVS HEALTH CORP

CVS Health streamlines oncology care, secures Omnicare’s restructuring, and boosts community wellness, positioning the company for sustained growth in U.S. healthcare.

CVS Health’s latest moves—Aetna’s rapid profit turnaround, 20‑year Project Health screenings, and a women‑focused weight‑management program—boost investor confidence and set a new standard for community‑centric care.

Discover how CVS Health’s nationwide COVID‑19 vaccine rollout, family health tips, oncology investment, and community partnerships boost public health and innovation.

CVS Health Q2 2026 revenue hits $106.1B, EPS up to $2.58, and the company lifts its full‑year earnings outlook amid stronger pharmacy‑benefits and Aetna growth.

CVS Health’s latest moves to standardize prior‑authorization rules with UnitedHealth, a 3.2% share rise, and a PR spat with Planned Parenthood highlight its growing influence and investor appeal in the health‑care market.

CVS Health Corp sees a surge in institutional buying, steep options volume, and a price‑target cut amid a strategic pivot and FTC scrutiny—can the pharmacy giant navigate this turbulence?…

CVS Health’s stock drops as institutional selling, a CEO retirement and a new pharmacy‑only store rollout raise investor uncertainty. Find out how the strategy could reshape community care.

CVS Health’s recent $10B Oak Street Health deal sparks insider‑trading claims and a $45M PBM settlement, testing its growth plans amid rising regulatory scrutiny.

CVS Health Corp’s latest moves—TrumpRx expansion, Aetna’s award and mixed institutional trading—show a high‑valuation play seeking growth amid PBM volatility.

CVS Health’s new TrumpRx partnership, biosimilar swaps, and veteran‑access plan show how the pharmacy giant is reshaping drug pricing, cutting costs and boosting competition while facing regulatory scrutiny and investor pressure.